IMMray® PanCan-d Test Receives Final Approval
Immunovia, Inc., the American subsidiary of Immunovia AB (Nasdaq Stockholm: IMMNOV), announced that it has received final approval to begin patient testing for the IMMray® PanCan-d test – the first blood test on the market dedicated to the early detection of pancreatic cancer. Approximately 10-15% of all pancreatic cancer cases are attributed to a familial… Read More »IMMray® PanCan-d Test Receives Final Approval